Table 2.
Detailed cohort characteristics
| All (n = 36) | LD GM-CSF (n = 6) | LD Alhydrogel (n = 6) | MD GM-CSF (n = 6) | MD Alhydrogel (n = 6) | HD GM-CSF (n = 6) | HD Alhydrogel (n = 6) | |
|---|---|---|---|---|---|---|---|
| Age (years) | 44.0 (38.5–49.7) | 45.2 (39.7–50.5) | 44.4 (35.8–54.5) | 37.2 (27.8–46.9) | 49.7 (45.7–50.8) | 44.0 (41.5–46.0) | 40.1 (38.0–45.3) |
| Time since diagnosis (years) | 5.2 (3.1–9.8) | 3.9 (2.2–6.3) | 5.9 (3.0–7.29 | 4.1 (2.8–11.0) | 6.4 (3.4–9.1) | 5.9 (3.2–15.8) | 9.8 (4.6–15.9) |
| Time on ART (years) | 2.3 (1.4–3.9) | 2.0 (1.4–2.8) | 2.5 (1.7–2.6) | 2.3 (1.3–2.7) | 3.3 (1.9–4.8) | 1.3 (1.1–1.5) | 4.8 (2.0–7.4) |
| Nadir CD4 (cells/μl) | 290 (234–360) (n = 35) | 318 (230–475) | 357 (268–366) | 283 (269–295) (n = 5) | 275 (234–343) | 258 (228–380) | 302 (219–340) |
| CD4 (cells/μl) | 626 (529–758) | 679 (580–1006) | 656 (563–728) | 610 (546–713) | 529 (498–596) | 654 (624–840) | 706 (514–821) |
| CD8 (cells/μl) | 1051 (794–1250) | 1178 (798–2268) | 1002 (764–1173) | 921 (345–1256) | 1104 (795–1308) | 905 (658–1040) | 1195 (932–1258) |
| HIV RNA (copies/ml) | 0b (0 - <20) | 0 (0 - <20) | 0 (0–0) | 0 (0 - <20) | 0 (0 - <20) | 0 (0–0) | 0 (0 - <20) |
| PreART CD4 (cells/μl)a | 341 (210–845) (n = 34) | 358 (211–845) | 360 (268–840) | 295 (210–398) (n = 5) | 301 (220–480) | 306 (226–454) (n = 5) | 370 (266–840) |
| PreART RNA (copies/ml)a | 7.3 × 104 (1.7 102–7.3 105) (n = 35) | 8.0 × 104 (1.2 104–1.0 105) | 3.3 × 104 (1.7 102–7.2 105) | 1.5 × 105 (2.6 104−3.4 105) (n = 5) | 1.1 × 105 (7.3 104–4.3 105) | 4.8 104 (1.7 104–3.0 105) | 3.2 × 104 (2.3 103–7.3 105) |
| Anti-Vacc-C5 AB (ng/ml) | 1433 (390–4678) | 390 (390–1934) | 1341 (390–2396) | 723 (390–4894) | 1394 (458–5282) | 1239 (390–4401) | 7309 (3280–9772) |
Median (interquartile range)
aMedian (min-max)
b0 implies undetectable PCR product